November 26, 2019

Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.

Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

January 31, 2019

Radiation therapy, the use of high-energy particles or waves, such as x-rays, gamma rays, electrons, or protons, has long been used to treat cancer. From as early as the 20th Century, physicians have given regular doses of radiation to greatly improve the patient’s cha...

August 23, 2018

The Massachusetts Radiation Control Program (RCP), in conjunction with the U.S. Nuclear Regulatory Commission (NRC), has approved Alpha Tau Medical’s Alpha DaRT cancer treatment as a Sealed Source and Device (SSD). 

Granting of th...

August 22, 2018

The new Sealed Source and Device (SSD) approval enables the commencement of clinical trials in leading hospitals across the U.S. with the company’s breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy).  

Boston, MA, August 21st 2018 --...

March 23, 2018

At the first Alpha Tau Medical Summit, international participants from leading cancer centers discussed the application of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) to various cancer types.

The Biomed Company Alpha Tau Medical, which developed a highly eff...

July 17, 2017

Following the promising preliminary clinical results, showing the ability of Alpha DaRT to effectively and safely destroy solid tumors, Alpha Tau Medical raises more capital than planned.

Alpha Tau Medical Ltd. has raised 20% more capital than planned for its Alpha DaRT...

Please reload

Please reload

Sign up
Featured Posts

Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices

April 11, 2019

Please reload

Please reload

Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon